Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of SBK007 Tablets in Seasonal Allergic Rhinitis
CTR20254784Phase 2Completed
- Sponsor
- Chengdu Shibeikang Biopharmaceutical Technology
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SBK007 in allergic rhinitis (AR), sponsored by Chengdu Shibeikang Biopharmaceutical Technology. Started Mar 2026; status: completed.
02
Drugs
SBK007
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on CTR20254784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254784.